Clin2
NCT07230106Possibly a fitRecruiting

Study of 3 drugs for men with prostate cancer

Prostate Cancer

Treatments studied

Part of Cancer, Kidney & urinary clinical trials.

This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
218 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • Men aged 18 to 80 with a confirmed prostate cancer that is not a neuroendocrine or small cell type
  • Already on continuous hormone therapy (ADT) or had their testicles removed
  • PSA level of 1 ng/mL or more at screening
  • Must be able to provide a tumor tissue sample for genetic testing
  • Good overall health (able to do daily activities independently)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06689163Recruiting· Phase 1/Phase 2
Study of HRS-1167 with abiraterone for metastatic prostate cancer

This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.

Hefei, Anhui
NCT06568094Recruiting· Phase 1/Phase 2
Study of HRS-5041 with other drugs for advanced prostate cancer

This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.

Harbin, Heilongjiang
NCT07407283Recruiting· Phase 1/Phase 2
Study of SHR-4394 combination therapy for prostate cancer

This trial tests a new drug called SHR-4394 combined with standard hormone therapy for men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination can help control the cancer.

Chengdu, Sichuan
NCT06783829Recruiting· Phase 1
Study of SHR-4394 for men with advanced prostate cancer

This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.

Chengdu, Sichuan
NCT07735377Recruiting· Phase 1
Study of SHR-6914 for Prostate Cancer

This study tests a new drug called SHR-6914 in men with prostate cancer that has spread. The goal is to see if it is safe and helps shrink or control the cancer, and to learn how the body processes it.

Guangzhou, Guangdong
NCT06473259Recruiting
Comparing treatments for hormone-sensitive metastatic prostate cancer

This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.

Orbassano, Torino

Hear when a new Prostate cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.